JP2010516662A5 - - Google Patents

Download PDF

Info

Publication number
JP2010516662A5
JP2010516662A5 JP2009545975A JP2009545975A JP2010516662A5 JP 2010516662 A5 JP2010516662 A5 JP 2010516662A5 JP 2009545975 A JP2009545975 A JP 2009545975A JP 2009545975 A JP2009545975 A JP 2009545975A JP 2010516662 A5 JP2010516662 A5 JP 2010516662A5
Authority
JP
Japan
Prior art keywords
prevention
products
treatment
herpes
bronchoconstriction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009545975A
Other languages
English (en)
Japanese (ja)
Other versions
JP5264773B2 (ja
JP2010516662A (ja
Filing date
Publication date
Priority claimed from FR0700357A external-priority patent/FR2911604B1/fr
Application filed filed Critical
Publication of JP2010516662A publication Critical patent/JP2010516662A/ja
Publication of JP2010516662A5 publication Critical patent/JP2010516662A5/ja
Application granted granted Critical
Publication of JP5264773B2 publication Critical patent/JP5264773B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009545975A 2007-01-19 2008-01-17 N−(ヘテロアリール)−1−ヘテロアリール−1h−インドール−2−カルボキサミドの誘導体、これらの調製およびこれらの治療用途 Expired - Fee Related JP5264773B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR07/00357 2007-01-19
FR0700357A FR2911604B1 (fr) 2007-01-19 2007-01-19 Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
PCT/FR2008/000055 WO2008107544A1 (fr) 2007-01-19 2008-01-17 Derives de n-(heteroaryl)-1-heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique

Publications (3)

Publication Number Publication Date
JP2010516662A JP2010516662A (ja) 2010-05-20
JP2010516662A5 true JP2010516662A5 (OSRAM) 2013-05-02
JP5264773B2 JP5264773B2 (ja) 2013-08-14

Family

ID=38283097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545975A Expired - Fee Related JP5264773B2 (ja) 2007-01-19 2008-01-17 N−(ヘテロアリール)−1−ヘテロアリール−1h−インドール−2−カルボキサミドの誘導体、これらの調製およびこれらの治療用途

Country Status (11)

Country Link
US (1) US7868024B2 (OSRAM)
EP (1) EP2125787B1 (OSRAM)
JP (1) JP5264773B2 (OSRAM)
AR (1) AR064937A1 (OSRAM)
CL (1) CL2008000127A1 (OSRAM)
ES (1) ES2624795T3 (OSRAM)
FR (1) FR2911604B1 (OSRAM)
PE (1) PE20081689A1 (OSRAM)
TW (1) TW200900058A (OSRAM)
UY (1) UY30874A1 (OSRAM)
WO (1) WO2008107544A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926555B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) * 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PE20190736A1 (es) 2012-06-13 2019-05-23 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2025526401A (ja) * 2022-07-25 2025-08-13 ケイマン ケミカル カンパニー, インコーポレーテッド sPLA2-X阻害剤としての新規複素環

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343782B1 (en) 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
PL373484A1 (en) 2001-12-10 2005-09-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP2033953A1 (en) * 2002-02-15 2009-03-11 Glaxo Group Limited Vanilloid receptor modulators
ES2337254T3 (es) * 2003-02-14 2010-04-22 Glaxo Group Limited Derivados de carboxamida.
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
FR2897061B1 (fr) * 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.

Similar Documents

Publication Publication Date Title
JP2010516662A5 (OSRAM)
WO2012103216A3 (en) Apparatus and methods for assisting breathing
CY1110519T1 (el) Συνδυασμος r,r-γλυκοπυρρολικου, ρολιπραμης και βουδεσονιδης για την αντιμετωπιση φλεγμονωδων νοσων
IL190835A0 (en) Sulfonamide derivatives, their preparation and use
EP2491932A3 (en) Use of biomarkers for monitoring the course of treatment of a pulmonary disease upon treatment with treprostinil
WO2014151456A3 (en) Treatment of inflammatory diseases
CL2007002274A1 (es) Compuestos derivados del acido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acetico; composicion farmaceutica; y uso para la prevencion y/o tratamiento de enfermedades alergicas e inmunes, tales como asma, epoc y rinitis entre otras.
WO2010151640A3 (en) Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
JP2016540749A5 (OSRAM)
WO2010062995A3 (en) Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
WO2014182928A3 (en) Stat6 inhibitors
WO2008035315A3 (en) Inhibitors of phosphodiesterase type-iv
EP2120935A4 (en) NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA
EP2125728A4 (en) NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA
WO2006086609A3 (en) Inhibitors of tryptase
MX2021015553A (es) Inhibidores de arginasa novedosos.
PL1844032T3 (pl) Pochodne N-hydroksyamidu i ich zastosowanie
EP3172191A4 (en) A novel compound isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the composition comprising the same for preventing or treating allergy disease, inflammatory disease, asthma or chronic obstructive pulmonary disease and the use thereof
WO2014062143A3 (en) Combinations of glycopyrrolate and an anticholinergic agent
WO2008035316A3 (en) Phosphodiesterase inhibitors
HK1138005A (en) Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma
HK1136974A (en) Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma
CN302001527S (zh) 栏杆(兰桂圆)
AR062566A1 (es) Compuestos de pirazolo (3,4-b]piridina, un procedimiento para su preparacion y composicion farmaceutica